Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine in hyaluronan-high metastatic pancreatic ductal adenocarcinoma
2015-004068-13Phase 3Terminated
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing PEGPH20 + nab-paclitaxel + gemcitabine with Placebo + nab-paclitaxel + gemcitabine (2 arms). Primary endpoint: Progression-free survival. Started Feb 2016; status: terminated.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2015-004068-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004068-13.